Intellia Therapeutics IncChange company Symbol lookupSelect an option...NTLA Intellia Therapeutics IncTTWO Take-Two Interactive Software IncBZUN Baozun IncCOMSW ComSovereign Holding Equity Warrants Exp 18th Dec 2025 *W EXP 12/18/2025DYN Dyne Therapeutics IncC-K Citigroup IncPII Polaris IncHSDT Helius Medical Technologies IncWSBC WesBanco IncHQGE Big M Entertainment CorpGo
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). It is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned chimeric antigen receptor T (CAR-T) cell candidate, NTLA-6001 targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin's lymphoma.
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| February 23, 2023 | Q4 2022 Earnings Release | -$1.40 | -$1.70 to -$0.83 | -$1.09 |
| November 3, 2022 | Q3 2022 Earnings Release | -$1.49 | -$1.56 to -$0.283 | -$0.97 |
| August 4, 2022 | Q2 2022 Earnings Release | -$1.33 | -$2.07 to -$0.98 | -$1.01 |
| May 5, 2022 | Q1 2022 Earnings Release | -$1.96 | -$1.90 to -$0.728 | -$0.69 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.